These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 31125418)

  • 1. Defining EGFR amplification status for clinical trial inclusion.
    French PJ; Eoli M; Sepulveda JM; de Heer I; Kros JM; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Weller M; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; van den Bent M
    Neuro Oncol; 2019 Oct; 21(10):1263-1272. PubMed ID: 31125418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Biomarker Assays for
    Lassman AB; Roberts-Rapp L; Sokolova I; Song M; Pestova E; Kular R; Mullen C; Zha Z; Lu X; Gomez E; Bhathena A; Maag D; Kumthekar P; Gan HK; Scott AM; Guseva M; Holen KD; Ansell PJ; van den Bent MJ
    Clin Cancer Res; 2019 Jun; 25(11):3259-3265. PubMed ID: 30796037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting EGFR gene amplification using a fluorescence in situ hybridization platform based on digital microfluidics.
    Shen C; Zhan C; Tong Z; Yin H; Hui J; Qiu S; Li Q; Xu X; Ma H; Wu Z; Shi N; Mao H
    Talanta; 2024 Mar; 269():125444. PubMed ID: 38042143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods.
    Lih CJ; Si H; Das B; Harrington RD; Harper KN; Sims DJ; McGregor PM; Camalier CE; Kayserian AY; Williams PM; He HJ; Almeida JL; Lund SP; Choquette S; Cole KD
    J Mol Diagn; 2016 Sep; 18(5):753-761. PubMed ID: 27455875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of
    Heydt C; Becher AK; Wagener-Ryczek S; Ball M; Schultheis AM; Schallenberg S; Rüsseler V; Büttner R; Merkelbach-Bruse S
    Comput Struct Biotechnol J; 2019; 17():1339-1347. PubMed ID: 31762957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes.
    Pant A; Lim M
    Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2312277120. PubMed ID: 37672559
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
    Leonetti A; Sharma S; Minari R; Perego P; Giovannetti E; Tiseo M
    Br J Cancer; 2019 Oct; 121(9):725-737. PubMed ID: 31564718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
    Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
    Lassman AB; Aldape KD; Ansell PJ; Bain E; Curran WJ; Eoli M; French PJ; Kinoshita M; Looman J; Mehta M; Muragaki Y; Narita Y; Ocampo C; Roberts-Rapp L; Song M; Vogelbaum MA; Walenkamp AME; Wang TJC; Zhang P; van den Bent MJ
    J Neurooncol; 2019 Aug; 144(1):205-210. PubMed ID: 31273577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A troublesome burden, the amplification of EGFR in glioblastoma!
    Lobbous M; Nabors LB
    Neuro Oncol; 2020 May; 22(5):594-595. PubMed ID: 32144420
    [No Abstract]   [Full Text] [Related]  

  • 11.
    Wu S; Gao F; Zheng S; Zhang C; Martinez-Ledesma E; Ezhilarasan R; Ding J; Li X; Feng N; Multani A; Sulman EP; Verhaak RG; de Groot JF; Heffernan TP; Yung WKA; Koul D
    Clin Cancer Res; 2020 Mar; 26(6):1395-1407. PubMed ID: 31852834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma.
    Fares J; Wan Y; Mair R; Price SJ
    Brain Commun; 2024; 6(2):fcae108. PubMed ID: 38646145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
    Wilcock DM; Goold E; Zuromski LM; Davidson C; Mao Q; Sirohi D
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):338-344. PubMed ID: 38605523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects.
    Penkova A; Kuziakova O; Gulaia V; Tiasto V; Goncharov NV; Lanskikh D; Zhmenia V; Baklanov I; Farniev V; Kumeiko V
    Front Mol Biosci; 2023; 10():1216102. PubMed ID: 37908227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
    Sohn B; Park K; Ahn SS; Park YW; Choi SH; Kang SG; Kim SH; Chang JH; Lee SK
    J Neurooncol; 2023 Sep; 164(2):341-351. PubMed ID: 37689596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.
    Sahm F; Brandner S; Bertero L; Capper D; French PJ; Figarella-Branger D; Giangaspero F; Haberler C; Hegi ME; Kristensen BW; Kurian KM; Preusser M; Tops BBJ; van den Bent M; Wick W; Reifenberger G; Wesseling P
    Neuro Oncol; 2023 Oct; 25(10):1731-1749. PubMed ID: 37279174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of resistant mechanisms in an
    Li Y; Xu Z; Xie T; Xing P; Ying J; Li J
    Front Oncol; 2022; 12():937282. PubMed ID: 36033496
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma.
    Suzuki H; Ono T; Koyota S; Takahashi M; Sugai T; Nanjo H; Shimizu H
    J Neurooncol; 2022 Sep; 159(2):397-408. PubMed ID: 35779193
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Hölzl D; Hutarew G; Zellinger B; Alinger-Scharinger B; Schlicker HU; Schwartz C; Sotlar K; Kraus TFJ
    Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.